HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NPD StriVectin report

This article was originally published in The Rose Sheet

Executive Summary

StriVectin-SD sales in U.S. department stores were $30 mil. during the first five months of 2004, though fewer than 5% of women are aware of the anti-aging and stretch mark cream, and only 12% of those own it, NPD Group reports in "Beyond Botox: Understanding the StriVectin-SD Consumer," released July 19. Klein-Becker's StriVectin originally launched in health food stores as a stretch mark treatment, but approximately 75% of buyers use the product to fight facial lines and wrinkles, market research firm says. Since its department store debut last May, StriVectin "has become an important player in the prestige skin care industry," NPD notes, adding the formula "has managed to surpass blockbuster prestige skin care products in terms of dollar volume"...

You may also be interested in...



Is StriVectin Better Than Botox? Not Without NDA Approval, FDA Says

Klein-Becker's signature statement for StriVectin-SD anti-aging cream - "Better than Botox?" - constitutes a structure/function claim that would require the product to be regulated as a drug, the agency states in a 1warning letter recently posted on its Web site

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel